Nanohale AG (FYB) | WebDisclosure

Basculer en Français

8205	Companies
109399	Keywords
51579	Articles
60261	Press releases

Home
Companies
Nanohale AG

BRIEF

published on 09/30/2024 at 07:35, 1 month 4 days ago

Formycon and Fresenius Kabi Receive FDA Approval for Biosimilar Otulfi

FDA Approval Biosimilar Formycon Fresenius Kabi Otulfi
PRESS RELEASE

published on 09/30/2024 at 07:30, 1 month 4 days ago

Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
Formycon and Fresenius Kabi receive FDA approval for FYB202/OtulfiTM (ustekinumab-aauz) to treat several conditions including Crohn’s disease and psoriasis, expanding biosimilar market presence

FDA Approval Biosimilar Formycon Fresenius Kabi Ustekinumab
BRIEF

published on 09/27/2024 at 22:01, 1 month 6 days ago

FDA Grants Approval for Stelara® Biosimilar FYB202/OtulfiTM

FDA Approval Pharmaceutical Formycon AG Biosimilar Stelara®
BRIEF

published on 09/27/2024 at 22:01, 1 month 6 days ago

La FDA approuve le biosimilaire Stelara® FYB202/OtulfiTM

Formycon AG Approbation De La FDA Pharmaceutique Biosimilaire Stelara®
PRESS RELEASE

published on 09/27/2024 at 21:56, 1 month 7 days ago

EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
FDA grants approval for Stelara Biosimilar FYB202/Otulfi (ustekinumab-aauz) by Formycon AG. Approval based on comprehensive data evaluation. Contact: Sabrina Mueller, Formycon AG

FDA Approval Formycon AG FYB202 Stelara Biosimilar Sabrina Mueller
BRIEF

published on 09/27/2024 at 09:05, 1 month 7 days ago

La Commission européenne approuve le biosimilaire FYB202/Otulfi® de Formycon et Fresenius Kabi

Formycon Fresenius Kabi FYB202 Ustekinumab Commission Européenne
BRIEF

published on 09/27/2024 at 09:05, 1 month 7 days ago

European Commission Approves Formycon and Fresenius Kabi's Biosimilar FYB202/Otulfi®

European Commission Formycon Fresenius Kabi FYB202 Ustekinumab
PRESS RELEASE

published on 09/27/2024 at 09:00, 1 month 7 days ago

Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases
Formycon and Fresenius Kabi secure European Commission approval for FYB202/Otulfi® (ustekinumab) to treat inflammatory diseases, expanding biosimilar portfolio

Biosimilar Formycon Fresenius Kabi Ustekinumab European Commission Approval
BRIEF

published on 09/17/2024 at 06:55, 1 month 17 days ago

Formycon to Present FYB202 Biosimilar Data at EADV Congress and UEG Week

Clinical Data Biosimilar Formycon FYB202 Ustekinumab
BRIEF

published on 09/17/2024 at 06:55, 1 month 17 days ago

Formycon présentera les données biosimilaires FYB202 au congrès EADV et à la semaine UEG

Formycon FYB202 Ustekinumab Biosimilaire Données Cliniques

Accesswire

Published on 11/04/2024 at 21:45, 12 minutes ago

Hank Payments Responds to Press Release Issued By Melrose Ventures
Published on 11/04/2024 at 21:30, 27 minutes ago

Forward Water Technologies Corp. Announces Shares for Interest Debt Settlement
Published on 11/04/2024 at 20:45, 1 hour 12 minutes ago

Koilink Technologies Inc. Appoints Transfer Online Inc. as New Transfer Agent, Enhancing Shareholder Services Amid Progress Toward Public Listing
Published on 11/04/2024 at 19:00, 2 hours 57 minutes ago

Arctic IT Government Solutions Selected as an Information Technology Support Services Contractor for the U.S. Department of the Interior, Bureau of Indian Affairs
Published on 11/04/2024 at 18:15, 3 hours 42 minutes ago

Al Salam Bank Launches ASB Capital: A New Asset Management Firm in the DIFC with AUMs of USD 4.5 Billion

View all ACCESSWIRE

EQS Group

Published on 11/04/2024 at 21:15, 42 minutes ago

EQS-Adhoc: LEG Immobilien SE: Acquisition of Brack Capital Properties N.V. through the conclusion of a share purchase agreement and a tender commitment in the event of a public offer
Published on 11/04/2024 at 19:00, 2 hours 57 minutes ago

EQS-Adhoc: Salzgitter Aktiengesellschaft: Potential voluntary public takeover bid to the shareholders of Salzgitter AG
Published on 11/04/2024 at 19:00, 2 hours 57 minutes ago

PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 28 OCTOBRE 2024 au 01 NOVEMBRE 2024
Published on 11/04/2024 at 19:00, 2 hours 57 minutes ago

PATRIMOINE ET COMMERCE: INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF
Published on 11/04/2024 at 18:47, 3 hours 9 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 11/04/2024 at 18:13, 3 hours 44 minutes ago

Thales : lancement de l’opération 2024 d’actionnariat salarié
Published on 11/04/2024 at 18:13, 3 hours 44 minutes ago

Thales: Launch of the 2024 Employee Share Ownership Plan
Published on 11/04/2024 at 18:11, 3 hours 45 minutes ago

Monthly disclosure of the total number of shares and voting rights - 31/10/2024
Published on 11/04/2024 at 18:11, 3 hours 45 minutes ago

Déclaration mensuelle des actions et droits de vote – 31/10/2024
Published on 11/04/2024 at 17:45, 4 hours 12 minutes ago

Disclosure of trading in own shares from October 29th, 2024, to November 1st, 2024. Detailed information per transaction.

View all LES ECHOS COMFI WIRE